|
|
|
|
| LEADER |
02085nam a2200217 u 4500 |
| 001 |
EB002002131 |
| 003 |
EBX01000000000000001165032 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Canagliflozin (Invokana) for type 2 diabetes mellitus
|h Elektronische Ressource
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c September 2015, 2015
|
| 300 |
|
|
|a 1 PDF file (58 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Common drug review clinical review report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK349575
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Canagliflozin is the first sodium-glucose cotransporter-2 (SGLT2) inhibitor to be approved for use in Canada. Canagliflozin is indicated for patients with type 2 diabetes to improve glycemic control as monotherapy or in combination with metformin; a sulfonylurea; metformin and a sulfonylurea; metformin and pioglitazone; or insulin (with or without metformin) when these drugs do not provide adequate glycemic control. The recommended starting dose is 100 mg once daily. A dose of 300 mg once daily may be considered for patients who have tolerated a dose of 100 mg once daily and who need tighter glycemic control, provided they have an estimated glomerular filtration rate (eGFR) of e 60 mL/min/1.73 m2 and have a low risk of adverse reactions associated with reduced intravascular volume. Canagliflozin is contraindicated in renally impaired patients who have an eGFR of less than 45 mL/min/1.73 m2, have end-stage renal disease, or are on dialysis. The current CADTH Common Drug Review (CDR) submission for canagliflozin is for use in combination with metformin and a sulfonylurea in adult patients with type 2 diabetes mellitus to improve glycemic control when diet, exercise, and dual therapy do not provide adequate glycemic control
|